Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response
暂无分享,去创建一个
Mahmoud Abbas | Arnulf Stenzl | Jörg Hennenlotter | J. Serth | V. Grünwald | M. Kuczyk | A. Stenzl | A. Merseburger | J. Hennenlotter | I. Peters | Markus A Kuczyk | Axel S Merseburger | Natalia Dubrowinskaja | Kai Gebauer | Inga Peters | Ralph Scherer | Hossein Tezval | Viktor Grünwald | Jürgen Serth | M. Abbas | N. Dubrowinskaja | H. Tezval | R. Scherer | K. Gebauer
[1] M. Galsky. A prognostic model for metastatic renal-cell carcinoma. , 2013, The Lancet. Oncology.
[2] A. Papatsoris,et al. Molecular Pathogenetics of Renal Cancer , 2006, American Journal of Nephrology.
[3] Juna Lee,et al. Neurofilament Heavy Polypeptide Regulates the Akt-β-Catenin Pathway in Human Esophageal Squamous Cell Carcinoma , 2010, PloS one.
[4] W. Thoenes,et al. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. , 1986, Pathology, research and practice.
[5] D. Gutmann,et al. Promoter hypermethylation of the potential tumor suppressor DAL‐1/4.1B gene in renal clear cell carcinoma , 2006, International journal of cancer.
[6] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[7] D. Bostwick,et al. Neurofilament heavy chain-like messenger RNA and protein are present in benign prostate and down-regulated in prostatic carcinoma. , 1997, Cancer Research.
[8] Ammar Al-Chalabi,et al. Neurofilaments and neurological disease. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.
[9] Susumu Goto,et al. The KEGG databases at GenomeNet , 2002, Nucleic Acids Res..
[10] J. Serth,et al. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression , 2012, BJU international.
[11] J. Gu,et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma , 2010, Oncogene.
[12] B. Rini,et al. External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Berges,et al. Review of the Multiple Aspects of Neurofilament Functions, and their Possible Contribution to Neurodegeneration , 2008, Molecular Neurobiology.
[14] T. Choueiri,et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.
[15] L. Schwartz,et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[17] A. Viale,et al. Epigenetic expansion of VHL-HIF signal output drives multi-organ metastasis in renal cancer , 2012, Nature Medicine.
[18] David B Seligson,et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma , 2007, Cancer.
[19] J. Herman,et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. , 2010, The American journal of pathology.
[20] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[21] Y. Lacasse,et al. From the authors , 2005, European Respiratory Journal.
[22] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[23] A. Ganser,et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. , 2012, European journal of cancer.
[24] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Kapur,et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. , 2013, The Lancet. Oncology.
[26] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[27] M. van Engeland,et al. Genetics and epigenetics of renal cell cancer. , 2008, Biochimica et biophysica acta.
[28] N. Clarke,et al. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma , 2008, British Journal of Cancer.
[29] N Clarke,et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma , 2011, Oncogene.
[30] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[31] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome , 2001, Nature.
[32] J. Serth,et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma , 2013, British Journal of Cancer.
[33] L. Sobin,et al. The TNM system: Our language for cancer care , 2002, Journal of surgical oncology.
[34] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.
[35] M. Kaminishi,et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history , 2009, Cancer.
[36] T. Dörk,et al. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence , 2012, Epigenetics.
[37] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[38] J. Larkin,et al. Epigenetic regulation in RCC: opportunities for therapeutic intervention? , 2012, Nature Reviews Urology.
[39] C. Ricketts,et al. Identification of Candidate Tumour Suppressor Genes Frequently Methylated in Renal Cell Carcinoma , 2009, Oncogene.
[40] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.